Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02695290 · ClinicalTrials.gov registry record · Phase 4
Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT02695290 is a Phase 4 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 1 participants.
The verdict
NCT02695290, a Phase 4 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
There is a medical need for improving treatment of poor performance status patients with EGFR driver mutations and documenting safety and tolerability of existing agents.
Interventions
- DRUG Afatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-03-17 |
| Est. Completion | 2016-08-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02695290
The ClinicalTrials.gov registry entry for NCT02695290 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Afatinib is the first listed.
NCT02695290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02695290 about?
NCT02695290 is a clinical study titled "Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)". There is a medical need for improving treatment of poor performance status patients with EGFR driver mutations and documenting safety and tolerability of existing agents.
What is the current status of trial NCT02695290?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2016-03-17. Estimated completion is 2016-08-26.
What interventions are being tested in trial NCT02695290?
The interventions under investigation include: Afatinib (DRUG).
Who is sponsoring clinical trial NCT02695290?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.